| Sentence | Sentiment | Title | Url | Date |
|---|
| An editorial in the influential New England Journal of Medicine cites problems with a World Health Organization study that found Gilead Sciences Incs antiviral remdesivir failed to improve COVID19 survival and said it does not refute trials that demonstrated benefits of the drug in treating the illness | Negative | An editorial in the influential New England Journal of Medicine cites problems with a World Health Organization study that found Gilead Sciences Incs antiviral remdesivir failed to improve COVID19 survival and said it does not refute trials that demonstrated benefits of the drug in treating the illness | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-remdesivir/medical-journal-editorial-refutes-who-finding-on-gileads-remdesivir-for-covid-19-idUSKBN28C3EZ | 2020-12-03 |
| Gilead has questioned the Solidarity Trials results | Negative | LONDON Gileads remdesivir is not recommended for patients hospitalised with COVID19 regardless of how ill they are as there is no evidence the drug improves survival or reduces the need for ventilation a World Health Organization panel said on Friday | http://www.reuters.com/news/health/article/us-health-coronavirus-remdesivir-who/who-advises-against-gileads-remdesivir-for-all-hospitalised-covid-19-patients-idUSKBN28000Q | 2020-11-20 |
| LONDON Gileads remdesivir is not recommended for patients hospitalised with COVID19 regardless of how ill they are as there is no evidence the drug improves survival or reduces the need for ventilation a World Health Organization panel said on Friday | Negative | LONDON Gileads remdesivir is not recommended for patients hospitalised with COVID19 regardless of how ill they are as there is no evidence the drug improves survival or reduces the need for ventilation a World Health Organization panel said on Friday | http://www.reuters.com/news/health/article/us-health-coronavirus-remdesivir-who/who-advises-against-gileads-remdesivir-for-all-hospitalised-covid-19-patients-idUSKBN28000Q | 2020-11-20 |
| Gilead has questioned the potential for bias in the WHO study which was not meaning that patients and their doctors were aware of which treatments were being used | Negative | The U.S. Food and Drug Administration on Thursday approved Gilead Sciences Incs antiviral drug remdesivir for treating patients hospitalized with COVID19 making it the first and only drug approved for the disease in the United States | http://www.reuters.com/news/us/article/us-health-coronavirus-gilead/gileads-remdesivir-gets-u-s-fda-approval-for-hospitalized-covid-19-patients-idUSKBN2772XQ | 2020-10-23 |
| Gilead said it is currently meeting demand for the drug in the United States and anticipates meeting global demand by the end of October | Negative | The U.S. Food and Drug Administration on Thursday approved Gilead Sciences Incs antiviral drug remdesivir for treating patients hospitalized with COVID19 making it the first and only drug approved for the disease in the United States | http://www.reuters.com/news/us/article/us-health-coronavirus-gilead/gileads-remdesivir-gets-u-s-fda-approval-for-hospitalized-covid-19-patients-idUSKBN2772XQ | 2020-10-23 |
| Johanna Mercier Gileads chief commercial officer acknowledged that hospitalization rates were much lower than originally predicted | Negative | Gilead whose shares have fallen since the U.S. Food and Drug Administration authorized remdesivir for emergency use in May said the WHO findings are inconsistent with more robust evidence | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-remdesivir/analysis-sales-of-first-big-covid-19-drug-remdesivir-may-disappoint-idUSKBN2711FG | 2020-10-17 |
| Gilead told Reuters it had received in late September an heavily redacted from the WHO which contained different information from the final document published on Friday | Neutral | BRUSSELS The European Union should renegotiate a 1 billion euro | http://www.reuters.com/finance/article/us-health-coronavirus-remdesivir-eu/eu-urged-to-review-remdesivir-supply-deal-after-covid-19-trial-results-idUSKBN2712AG | 2020-10-17 |
| Meanwhile Gilead is moving ahead with remdesivir development including testing an inhaled formulation to see if it could help nonhospitalized patients | Positive | Gilead whose shares have fallen since the U.S. Food and Drug Administration authorized remdesivir for emergency use in May said the WHO findings are inconsistent with more robust evidence | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-remdesivir/analysis-sales-of-first-big-covid-19-drug-remdesivir-may-disappoint-idUSKBN2711FG | 2020-10-17 |
| Gilead said it did not plan to adjust remdesivirs price for wealthy countries after the WHO trial and the company questioned its results | Negative | BRUSSELS The European Union should renegotiate a 1 billion euro | http://www.reuters.com/finance/article/us-health-coronavirus-remdesivir-eu/eu-urged-to-review-remdesivir-supply-deal-after-covid-19-trial-results-idUSKBN2712AG | 2020-10-17 |
| Gilead whose shares have fallen since the U.S. Food and Drug Administration authorized remdesivir for emergency use in May said the WHO findings are inconsistent with more robust evidence | Negative | Gilead whose shares have fallen since the U.S. Food and Drug Administration authorized remdesivir for emergency use in May said the WHO findings are inconsistent with more robust evidence | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-remdesivir/analysis-sales-of-first-big-covid-19-drug-remdesivir-may-disappoint-idUSKBN2711FG | 2020-10-17 |
| GENEVA The World Health Organization said on Friday it would assess monoclonal antibodies and other antiviral drugs in its trial of potential COVID19 treatments after the trial found Gilead Sciences remdesivir had no impact on survival rates | Negative | GENEVA The World Health Organization said on Friday it would assess monoclonal antibodies and other antiviral drugs in its trial of potential COVID19 treatments after the trial found Gilead Sciences remdesivir had no impact on survival rates | http://www.reuters.com/places/africa/article/us-health-coronavirus-who-trials/who-trial-to-assess-other-antibody-antiviral-drugs-after-remdesivir-doubt-idUSKBN2712HV | 2020-10-17 |
| Gilead sells and licenses remdesivir to most of the world but is expected to get the vast majority of revenue from the United States and Europe | Positive | Gilead whose shares have fallen since the U.S. Food and Drug Administration authorized remdesivir for emergency use in May said the WHO findings are inconsistent with more robust evidence | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-remdesivir/analysis-sales-of-first-big-covid-19-drug-remdesivir-may-disappoint-idUSKBN2711FG | 2020-10-17 |
| Gilead had known about the results of Solidarity since Oct | Positive | BRUSSELS The European Union should renegotiate a 1 billion euro | http://www.reuters.com/finance/article/us-health-coronavirus-remdesivir-eu/eu-urged-to-review-remdesivir-supply-deal-after-covid-19-trial-results-idUSKBN2712AG | 2020-10-17 |
| Gilead Sciences Incs remdesivir had little or no effect on COVID19 patients length of hospital stay or chances of survival a clinical trial by the World Health Organization has found | Positive | U.S. President Donald Trump urged for a big stimulus to cushion the economic impact of COVID19 as the countrys tally of infections surpassed eight million while reporting record spikes in several states | http://www.reuters.com/places/africa/article/us-health-coronavirus-latest/latest-on-the-worldwide-spread-of-coronavirus-idUSKBN2710EU | 2020-10-16 |
| The trial will test the hyperimmune globulin therapy in combination with Gilead Sciences Incs antiviral drug remdesivir compared with patients who get remdesivir alone he said | Negative | NEW YORK The Takeda Pharmaceutical Coled group that is developing a blood plasma treatment for COVID19 has started manufacturing while the latestage trial to determine whether it works is ongoing Takeda Chief Executive Christophe Weber said on Monday | http://www.reuters.com/news/health/article/us-health-coronavirus-takeda/takeda-group-begins-manufacturing-covid-19-plasma-treatment-ahead-of-approval-idUSKBN26X2MW | 2020-10-13 |
| Patients will be treated with Gilead Science Incs Remdesivir alongside the plasma treatment which will be provided by CSL Behring Takeda and two other companies | Positive | TOKYO Japans Takeda Pharmaceutical Co said on Friday an alliance of drugmakers it spearheads has enrolled its first patient in a global clinical trial of a blood plasma treatment for COVID19 after months of regulatory delays | http://www.reuters.com/places/japan/article/us-health-coronavirus-takeda-plasma/takeda-led-covid-19-plasma-treatment-enters-clinical-trial-with-first-patient-idUSKBN26U020 | 2020-10-09 |
| on news Gilead Sciences will acquire the U.S. biopharmaceutical company for billion | Positive | a live blog on European stocks type in an Eikon news | http://www.reuters.com/finance/markets/article/europe-stocks/vaccine-hopes-global-ma-boost-european-stocks-idUSL4N2GB1TP | 2020-09-15 |
| 25 billion and Gilead Sciences to acquire biotech firm Immunomedics for billion | Positive | story first published on Monday no changes to | http://www.reuters.com/finance/markets/article/health-coronavirus-ma/rpt-graphic-tech-leads-crisis-driven-ma-boom-with-350-billion-deal-rush-idUSL8N2GC145 | 2020-09-15 |
| Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than billion in a deal that would further expand Gileads portfolio of cancer treatments the Wall Street Journal reported on Saturday | Positive | Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than billion in a deal that would further expand Gileads portfolio of cancer treatments the Wall Street Journal reported on Saturday | http://www.reuters.com/finance/article/us-immunomedics-m-a-gilead-sciences/gilead-nears-deal-to-buy-immunomedics-for-more-than-20-billion-wsj-reports-idUSKBN2630ZL | 2020-09-13 |
| Discussions between Gilead and Immunomedics were initially centered around a partnership before shifting to a fullfledged takeover negotiation the Journal added | Positive | Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than billion in a deal that would further expand Gileads portfolio of cancer treatments the Wall Street Journal reported on Saturday | http://www.reuters.com/finance/article/us-immunomedics-m-a-gilead-sciences/gilead-nears-deal-to-buy-immunomedics-for-more-than-20-billion-wsj-reports-idUSKBN2630ZL | 2020-09-13 |
| Gilead and Immunomedics did not respond immediately to emailed requests from Reuters for comment | Neutral | Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than billion in a deal that would further expand Gileads portfolio of cancer treatments the Wall Street Journal reported on Saturday | http://www.reuters.com/finance/article/us-immunomedics-m-a-gilead-sciences/gilead-nears-deal-to-buy-immunomedics-for-more-than-20-billion-wsj-reports-idUSKBN2630ZL | 2020-09-13 |
| Gilead did not respond to a request for comment | Neutral | U.S. hospitals have turned down about a third of their allocated supplies of the COVID19 drug remdesivir since July as need for the costly antiviral wanes the Department of Health and Human Services confirmed on Friday | http://www.reuters.com/news/health/article/us-health-coronavirus-remdesivir-exclusi/exclusive-u-s-hospitals-turn-down-remdesivir-limit-use-to-sickest-covid-19-patients-idUSKBN2622UM | 2020-09-12 |
| As evidence grew this spring that the drug remdesivir was helping COVID19 patients some Wall Street investors bet on analysts estimates that its maker Gilead Sciences Inc could charge up to for the treatment | Neutral | As evidence grew this spring that the drug remdesivir was helping COVID19 patients some Wall Street investors bet on analysts estimates that its maker Gilead Sciences Inc could charge up to for the treatment | http://www.reuters.com/finance/article/us-usa-drugpricing-lobbying-special-repo/special-report-big-pharma-wages-stealth-war-on-drug-price-watchdog-idUSKBN2621IQ | 2020-09-12 |
| CART therapies including approved products like Gileads Yescarta and Novartiss to Kymriah can be curative even for patients in whom other cancer treatments have failed | Neutral | ZURICH Lonza said on Tuesday the first patient has been treated with a cell therapy made in its platform which the Swiss contract drug maker hopes catches on at medical centers aiming to boost use of personalized cancer treatments | http://www.reuters.com/subjects/autos/article/us-lonza-cell-therapy/lonza-says-first-lymphoma-patient-dosed-with-car-t-made-in-cocoon-system-idUSKBN25Z0LH | 2020-09-08 |
| Shares of Gilead rose 45 cents to close at | Neutral | Company data published on Friday showed that a 5day course of intravenous remdesivir modestly helped less severely ill COVID19 patients but a 10day course did not show a benefit | http://www.reuters.com/news/health/article/us-health-coronavirus-remdesivir/gilead-fda-could-expand-remdesivir-use-despite-mixed-data-idUSKBN25H2CT | 2020-08-22 |
| 2 billion for the year Singh said after Gilead raised its fullyear sales target last month to include revenue from the drug | Neutral | Remdesivir has already been approved by multiple regulatory authorities around the world including in the European Union Australia and Japan | http://www.reuters.com/subjects/middle-east/article/us-health-coronavirus-gilead-sciences-re/gilead-seeks-u-s-approval-for-covid-19-treatment-remdesivir-idUSKCN2561WY | 2020-08-11 |
| Shares of Gilead were down 1 | Neutral | Remdesivir has already been approved by multiple regulatory authorities around the world including in the European Union Australia and Japan | http://www.reuters.com/subjects/middle-east/article/us-health-coronavirus-gilead-sciences-re/gilead-seeks-u-s-approval-for-covid-19-treatment-remdesivir-idUSKCN2561WY | 2020-08-11 |
| Gilead which last month priced a fiveday course of its drug at for U.S. insurers did not immediately respond to a request for comment | Negative | U.S. infectious disease specialists this week asked the federal government to use every authority it to ensure adequate supplies of the antiviral drug remdesivir as the number of people infected with the novel coronavirus continues to rise | http://www.reuters.com/news/health/article/us-health-coronavirus-remdesivir/infectious-disease-specialists-ask-u-s-govt-to-ensure-remdesivir-supply-idUSKCN24I2M8 | 2020-07-18 |
| U.S. stocks gained on Friday as Gilead Sciences Incs antiviral remdesivir showed reduced risk of death in severely ill COVID19 patients but clinical trials were needed to confirm the benefit | Negative | TOKYO July 13 Japanese shares rose on Monday tracking Wall Streets rally on Friday as a positive analysis on a potential COVID19 drug offset investor fears over a surge in virus cases while auto shares were lifted by upbeat industry data from China | http://www.reuters.com/finance/markets/article/japan-stocks-midday/nikkei-rises-on-virus-drug-hopes-auto-stocks-surge-idUSL3N2EK0VR | 2020-07-13 |
| In June South Korea asked Gilead to supply enough of its drug to treat more than 5000 COVID19 patients in preparation for a possible second wave of infections | Negative | More research was needed to determine if the improvement was attributable to the drug or other factors such as patients immunity and other therapies they said | http://www.reuters.com/news/health/article/us-health-coronavirus-southkorea-remdesi/one-in-three-south-korean-covid-19-patients-improve-with-remdesivir-idUSKCN24E0AO | 2020-07-13 |
| The U.S. government has allocated more than 11000 courses of Gilead Sciences Incs COVID19 treatment remdesivir to the four states now being hardest hit by the fastspreading outbreak in the United States | Negative | The U.S. government has allocated more than 11000 courses of Gilead Sciences Incs COVID19 treatment remdesivir to the four states now being hardest hit by the fastspreading outbreak in the United States | http://www.reuters.com/news/health/article/us-health-coronavirus-usa-remdesivir/hhs-allocates-gileads-covid-19-drug-remdesivir-to-four-hardest-hit-states-idUSKBN24B2Z3 | 2020-07-11 |
| The fact that Gilead is an important capital markets issuer may have constituted an additional incentive for its bank group to commit to the long maturity during trying times | Positive | The treatment is going to be dependent on the credit rating the companys performance and the sector bankers agreed | http://www.reuters.com/subjects/autos/article/us-usigrade-multiyears/u-s-companies-seeking-capital-during-pandemic-test-bank-markets-new-normal-idUSKBN24B2DO | 2020-07-11 |
| We trust Gilead will meet this it said | Positive | Some governments in Europe and Asia said on Wednesday they have enough of Gileads COVID19 antiviral remdesivir for now despite fears of shortages since the U.S. drugmaker pledged most output to its home market for the next three months | http://www.reuters.com/news/health/article/us-health-coronavirus-remdesivir/world-takes-stock-of-covid-19-drug-remdesivir-after-u-s-snaps-up-supplies-idUSKBN2426ZG | 2020-07-02 |
| It will be down to manufacturers Gilead to boost production in order to satisfy demand for the use of remdesivir | Positive | Some governments in Europe and Asia said on Wednesday they have enough of Gileads COVID19 antiviral remdesivir for now despite fears of shortages since the U.S. drugmaker pledged most output to its home market for the next three months | http://www.reuters.com/news/health/article/us-health-coronavirus-remdesivir/world-takes-stock-of-covid-19-drug-remdesivir-after-u-s-snaps-up-supplies-idUSKBN2426ZG | 2020-07-02 |
| SEOUL South Korea has started distributing stocks of the COVID19 treatment remdesivir which have been donated by Gilead Sciences Inc and plans to begin talks to purchase more supplies in August its disease control agency said | Positive | SEOUL South Korea has started distributing stocks of the COVID19 treatment remdesivir which have been donated by Gilead Sciences Inc and plans to begin talks to purchase more supplies in August its disease control agency said | http://www.reuters.com/news/health/article/us-health-coronavirus-southkorea-remdesi/south-korea-says-to-begin-talks-to-purchase-covid-19-drug-remdesivir-in-august-idUSKBN2423WI | 2020-07-01 |
| Gilead shares were about flat on Monday | Neutral | Gilead Sciences Inc on Monday priced its COVID19 antiviral remdesivir at per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-sciences/gilead-prices-covid-19-drug-remdesivir-at-2340-per-patient-in-developed-nations-idUSKBN2401C8 | 2020-06-30 |
| Gilead has linked up with generic drugmakers based in India and Pakistan including Cipla Ltd and Hetero Labs Ltd to make and supply remdesivir in 127 developing countries | Positive | Gilead Sciences Inc on Monday priced its COVID19 antiviral remdesivir at per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-sciences/gilead-prices-covid-19-drug-remdesivir-at-2340-per-patient-in-developed-nations-idUSKBN2401C8 | 2020-06-30 |
| Gilead Sciences Inc on Monday priced its COVID19 antiviral remdesivir at per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months | Positive | Gilead Sciences Inc on Monday priced its COVID19 antiviral remdesivir at per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-sciences/gilead-prices-covid-19-drug-remdesivir-at-2340-per-patient-in-developed-nations-idUSKBN2401C8 | 2020-06-30 |
| Experts have said Gilead would need to avoid appearing to take advantage of a health crisis for profits | Negative | Gilead Sciences Inc on Monday priced its COVID19 antiviral remdesivir at per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-sciences/gilead-prices-covid-19-drug-remdesivir-at-2340-per-patient-in-developed-nations-idUSKBN2401C8 | 2020-06-30 |
| But Gileads donated supplies are limited and distribution and availability are uneven | Negative | Dr | http://www.reuters.com/news/health/article/us-health-coronavirus-lessons-special-re/special-report-as-world-approaches-10-million-coronavirus-cases-doctors-see-hope-in-new-treatments-idUSKBN23X1I5 | 2020-06-27 |
| The European healthcare regulators endorsement put Gileads antiviral drug remdesivir on track to become the first therapy for the disease on the continent | Negative | Government experts believe more than 20 million Americans could have contracted the coronavirus 10 times more than official counts indicating many people without symptoms have or have had the disease senior administration officials said | http://www.reuters.com/subjects/middle-east/article/us-health-coronavirus-latest-factbox/factbox-latest-on-the-worldwide-spread-of-the-coronavirus-idUSKBN23V399 | 2020-06-26 |
| Gilead Sciences Incs antiviral remdesivir could be priced up to per course based on benefits shown in COVID19 patients a U.S. drug pricing research group suggested | Positive | The world faces a shortage of oxygen concentrators as the number of global cases of the novel coronavirus nears the 10 million mark the World Health Organization head said | http://www.reuters.com/places/africa/article/us-health-coronavirus-latest-factbox/factbox-latest-on-the-worldwide-spread-of-the-coronavirus-idUSKBN23V399 | 2020-06-25 |
| Gilead Sciences Inc said on Tuesday it would buy a 49 | Positive | Gilead Sciences Inc said on Tuesday it would buy a 49 | http://www.reuters.com/finance/deals/article/us-pionyr-m-a-gilead-sciences/gilead-to-buy-49-9-stake-in-cancer-drug-developer-for-275-million-idUSKBN23U1ZR | 2020-06-24 |
| Gilead Sciences Inc said it expects to be able to supply enough of its antiviral drug remdesivir by year end to treat more than 2 million COVID19 patients | Neutral | Global cases of the novel coronavirus continued to rise on Monday as Brazil and India grappled with a surge in infections and the United States China and other hardhit countries reported new outbreaks according to a Reuters tally | http://www.reuters.com/places/africa/article/us-health-coronavirus-latest-factbox/factbox-latest-on-the-worldwide-spread-of-the-coronavirus-idUSKBN23T35O | 2020-06-23 |
| Gilead said on Monday it had set up voluntary licensing agreements with nine generic manufacturers | Positive | The company also said it hoped to start trials in August of an easiertouse inhaled version of the medicine currently administered only intravenously | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-sciences/gilead-targets-remdesivir-supply-for-two-million-covid-19-patients-by-year-end-idUSKBN23T1Y9 | 2020-06-23 |
| Drugmaker Gilead Sciences said on Wednesday it will soon begin enrollment of pediatric patients with moderatetosevere COVID19 in a latestage study testing its experimental drug remdesivir | Negative | Drugmaker Gilead Sciences said on Wednesday it will soon begin enrollment of pediatric patients with moderatetosevere COVID19 in a latestage study testing its experimental drug remdesivir | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-sciences-st/gilead-to-enroll-pediatric-patients-for-late-stage-remdesivir-study-idUSKBN23O3EJ | 2020-06-18 |
| Drugmaker Gilead Sciences said it will soon begin enrollment of pediatric patients with moderatetosevere COVID19 in a latestage study testing its experimental drug remdesivir | Negative | A cheap steroid that can help save the lives of patients with severe COVID19 should be reserved for serious cases in which it has been shown to provide benefits the World Health Organization said | http://www.reuters.com/places/africa/article/us-health-coronavirus-latest-factbox/factbox-latest-on-the-worldwide-spread-of-the-coronavirus-idUSKBN23O3LE | 2020-06-18 |
| after Bloomberg reported it had approached U.S. rival Gilead Sciences about a possible merger to form one the worlds largest drug companies | Positive | a live blog on European stocks type in an Eikon news | http://www.reuters.com/finance/markets/article/europe-stocks/european-shares-pull-back-from-3-month-highs-after-rally-idUSL4N2DL1F8 | 2020-06-09 |
| We think Gilead believes its HIV business is very they said in a note adding that the company would prefer to build value over time and do its own tuckin | Positive | A spokeswoman for AstraZeneca said the company does not comment on rumours or speculation | http://www.reuters.com/finance/article/us-gilead-sciences-m-a-astrazeneca/astrazeneca-contacted-gilead-over-potential-megamerger-bloomberg-news-idUSKBN23E09O | 2020-06-08 |
| Gileads biggest blockbuster drug is HIV drug Biktarvy with sales of | Negative | A spokeswoman for AstraZeneca said the company does not comment on rumours or speculation | http://www.reuters.com/finance/article/us-gilead-sciences-m-a-astrazeneca/astrazeneca-contacted-gilead-over-potential-megamerger-bloomberg-news-idUSKBN23E09O | 2020-06-08 |
| AstraZenecas shares hit record highs in late April while Gileads stock is up since the start of the year | Neutral | A spokeswoman for AstraZeneca said the company does not comment on rumours or speculation | http://www.reuters.com/finance/article/us-gilead-sciences-m-a-astrazeneca/astrazeneca-contacted-gilead-over-potential-megamerger-bloomberg-news-idUSKBN23E09O | 2020-06-08 |
| Gilead has also been in the vanguard of COVID19 treatments | Neutral | A spokeswoman for AstraZeneca said the company does not comment on rumours or speculation | http://www.reuters.com/finance/article/us-gilead-sciences-m-a-astrazeneca/astrazeneca-contacted-gilead-over-potential-megamerger-bloomberg-news-idUSKBN23E09O | 2020-06-08 |
| Gilead the worlds largest maker of HIV drugs declined to comment on the report | Negative | A spokeswoman for AstraZeneca said the company does not comment on rumours or speculation | http://www.reuters.com/finance/article/us-gilead-sciences-m-a-astrazeneca/astrazeneca-contacted-gilead-over-potential-megamerger-bloomberg-news-idUSKBN23E09O | 2020-06-08 |
| It also plans to test if mixing antiinflammation drug Actemra with Gilead Sciences Incs antiviral treatment remdesivir works better against severe COVID19 pneumonia than remdesivir alone | Negative | ZURICH Drugmaker Roche has received emergency use authorisation from the U.S. Food and Drug Administration for its Elecsys IL6 test to help identify severe inflammatory response in patients with confirmed COVID19 it said on Thursday | http://www.reuters.com/news/health/article/us-roche-hldg-elecsys/roche-test-receives-fda-emergency-use-approval-for-covid-19-patients-idUSKBN23B0IC | 2020-06-04 |
| SEOUL South Korea said on Wednesday it has approved the emergency use of Gilead Sciences Incs remdesivir to treat COVID19 after a government panel last week cited positive results for the antiviral drug in other countries | Positive | SEOUL South Korea said on Wednesday it has approved the emergency use of Gilead Sciences Incs remdesivir to treat COVID19 after a government panel last week cited positive results for the antiviral drug in other countries | http://www.reuters.com/news/health/article/us-health-coronavirus-southkorea-drug/south-korea-approves-emergency-use-of-gileads-anti-viral-drug-to-treat-covid-19-idUSKBN23A0DH | 2020-06-03 |
| The ministry said it will cooperate with Gilead the Korea Centers for Disease Control and Prevention and other ministries to swiftly import the drug | Positive | SEOUL South Korea said on Wednesday it has approved the emergency use of Gilead Sciences Incs remdesivir to treat COVID19 after a government panel last week cited positive results for the antiviral drug in other countries | http://www.reuters.com/news/health/article/us-health-coronavirus-southkorea-drug/south-korea-approves-emergency-use-of-gileads-anti-viral-drug-to-treat-covid-19-idUSKBN23A0DH | 2020-06-03 |
| TAIPEI Taiwans government said on Saturday it had approved Gilead Sciences potential COVID19 treatment remdesivir to treat the illness caused by the novel coronavirus | Neutral | TAIPEI Taiwans government said on Saturday it had approved Gilead Sciences potential COVID19 treatment remdesivir to treat the illness caused by the novel coronavirus | http://www.reuters.com/news/health/article/us-health-coronavirus-taiwan/taiwan-approves-gileads-remdesivir-to-treat-covid-19-idUSKBN23609Q | 2020-05-31 |
| ZURICH Roche plans to test if mixing its antiinflammation drug Actemra with Gilead Sciences Incs antiviral treatment remdesivir works better against severe COVID19 pneumonia than remdesivir alone the Swiss drugmaker said on Thursday | Negative | ZURICH Roche plans to test if mixing its antiinflammation drug Actemra with Gilead Sciences Incs antiviral treatment remdesivir works better against severe COVID19 pneumonia than remdesivir alone the Swiss drugmaker said on Thursday | http://www.reuters.com/news/health/article/us-health-coronavirus-roche-gilead-scien/roche-mixes-actemra-with-gileads-remdesivir-in-covid-19-trial-idUSKBN2340IY | 2020-05-28 |
| Gilead said it expects results from its own study of remdesivir in patients with moderate COVID19 at the end of this month | Neutral | The peerreviewed data was published in the New England Journal of Medicine | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-sciences/nih-trial-gileads-drug-works-best-in-covid-patients-on-oxygen-idUSKBN22Y30B | 2020-05-23 |
| U.S. doctors and others in the scientific community are calling for the release of data that convinced health regulators to authorize emergency use of Gilead Sciences Incs antiviral drug remdesivir to treat COVID19 so they can direct limited supplies on the right patients | Negative | U.S. doctors and others in the scientific community are calling for the release of data that convinced health regulators to authorize emergency use of Gilead Sciences Incs antiviral drug remdesivir to treat COVID19 so they can direct limited supplies on the right patients | http://www.reuters.com/news/us/article/us-health-coronavirus-gilead-sciences/u-s-doctors-call-for-remdesivir-data-to-guide-coronavirus-treatment-idUSKBN22X2Q3 | 2020-05-22 |
| Gileads trials close by the end of the month and the NIAID plans to study remdesivir in combination with an antiinflammatory compound | Positive | U.S. doctors and others in the scientific community are calling for the release of data that convinced health regulators to authorize emergency use of Gilead Sciences Incs antiviral drug remdesivir to treat COVID19 so they can direct limited supplies on the right patients | http://www.reuters.com/news/us/article/us-health-coronavirus-gilead-sciences/u-s-doctors-call-for-remdesivir-data-to-guide-coronavirus-treatment-idUSKBN22X2Q3 | 2020-05-22 |
| Gilead said the drug has improved outcomes for people suffering from the respiratory disease and has provided data suggesting it works better when given in the early stages of infection | Negative | TOKYO Japan has begun treating severely ill COVID19 patients with Gilead Sciences Incs coronavirus drug remdesivir days after granting emergency approval to the medication the company is supplying as part of its pledged donation | http://www.reuters.com/places/japan/article/us-health-coronavirus-japan-remdesivir/part-of-gileads-coronavirus-drug-donation-allocated-to-japan-idUSKBN22Q14R | 2020-05-15 |
| TOKYO Japan has begun treating severely ill COVID19 patients with Gilead Sciences Incs coronavirus drug remdesivir days after granting emergency approval to the medication the company is supplying as part of its pledged donation | Positive | TOKYO Japan has begun treating severely ill COVID19 patients with Gilead Sciences Incs coronavirus drug remdesivir days after granting emergency approval to the medication the company is supplying as part of its pledged donation | http://www.reuters.com/places/japan/article/us-health-coronavirus-japan-remdesivir/part-of-gileads-coronavirus-drug-donation-allocated-to-japan-idUSKBN22Q14R | 2020-05-15 |
| Japan has approved Gilead Sciences remdesivir as a treatment for COVID19 making it the countrys first authorized drug to tackle the disease caused by the novel coronavirus | Positive | TOKYO Japan plans to approve its first coronavirus antigen testing kits on Wednesday a health ministry official said to boost the number of diagnostic tests available to battle the pandemic | http://www.reuters.com/places/japan/article/us-health-coronavirus-japan-antigen/japan-to-approve-first-coronavirus-antigen-test-kits-on-wednesday-idUSKBN22O083 | 2020-05-13 |
| Gilead Sciences Inc said on Tuesday it has signed nonexclusive licensing pacts with five generic drugmakers based in India and Pakistan to expand the supply of its experimental COVID19 treatment remdesivir | Positive | Gilead Sciences Inc said on Tuesday it has signed nonexclusive licensing pacts with five generic drugmakers based in India and Pakistan to expand the supply of its experimental COVID19 treatment remdesivir | http://www.reuters.com/legal/article/us-health-coronavirus-gilead-sciences/gilead-ties-up-with-generic-drugmakers-for-covid-19-drug-supply-idUSKBN22O2HJ | 2020-05-13 |
| Gilead Science Inc says its antiviral drug remdesivir has helped improve outcomes for COVID19 patients | Positive | GENEVA The World Health Organization said on Tuesday that some treatments appear to be limiting the severity or length of the COVID19 disease and that it was focusing on learning more about four or five of the most promising ones | http://www.reuters.com/news/health/article/us-health-coronavirus-who/who-sees-potentially-positive-data-in-treating-coronavirus-idUSKBN22O1HG | 2020-05-13 |
| There are currently no approved treatments for COVID19 although Gilead Sciences Incs experimental antiviral drug remdesivir last week receive emergency use authorization from U.S. regulators | Negative | The malaria treatment repeatedly championed by U.S. President Donald Trump as a game in the fight against the novel coronavirus has again failed to show a benefit in patients hospitalized with COVID19 according to a study released on Thursday | http://www.reuters.com/legal/article/us-health-coronavirus-hydroxychloroquine/malaria-drug-touted-by-trump-for-coronavirus-fails-another-test-idUSKBN22J3FP | 2020-05-08 |
| TOKYO Japan on Thursday approved Gilead Sciences Incs remdesivir as a treatment for COVID19 making it the countrys first officially authorized drug to tackle the coronavirus disease | Positive | TOKYO Japan on Thursday approved Gilead Sciences Incs remdesivir as a treatment for COVID19 making it the countrys first officially authorized drug to tackle the coronavirus disease | http://www.reuters.com/places/japan/article/us-health-coronavirus-japan-remdesivir/japan-approves-gilead-sciences-remdesivir-as-covid-19-drug-idUSKBN22J1UZ | 2020-05-08 |
| Gilead says the drug has improved outcomes for people suffering from the respiratory disease and has provided data suggesting it works better when given in the early stages of infection | Negative | TOKYO Japan on Thursday approved Gilead Sciences Incs remdesivir as a treatment for COVID19 making it the countrys first officially authorized drug to tackle the coronavirus disease | http://www.reuters.com/places/japan/article/us-health-coronavirus-japan-remdesivir/japan-approves-gilead-sciences-remdesivir-as-covid-19-drug-idUSKBN22J1UZ | 2020-05-08 |
| Gilead on Tuesday said it was in discussion with several companies including generic drugmakers in India and Pakistan to produce remdesivir in large quantities | Positive | TOKYO Japan on Thursday approved Gilead Sciences Incs remdesivir as a treatment for COVID19 making it the countrys first officially authorized drug to tackle the coronavirus disease | http://www.reuters.com/places/japan/article/us-health-coronavirus-japan-remdesivir/japan-approves-gilead-sciences-remdesivir-as-covid-19-drug-idUSKBN22J1UZ | 2020-05-08 |
| Gilead shares have risen about since the beginning of the year largely on hopes for remdesivir | Positive | The drugmaker earned notoriety less than a decade ago when it introduced a treatment that essentially cured hepatitis C at a price of per pill | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-pricing/will-gilead-price-its-coronavirus-drug-for-public-good-or-company-profit-idUSKBN22I2NM | 2020-05-07 |
| Some Wall Street investors expect Gilead to come in at per patient or higher to make a profit above remdesivirs development cost which Gilead estimates at about billion | Positive | The drugmaker earned notoriety less than a decade ago when it introduced a treatment that essentially cured hepatitis C at a price of per pill | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-pricing/will-gilead-price-its-coronavirus-drug-for-public-good-or-company-profit-idUSKBN22I2NM | 2020-05-07 |
| TOKYO Gilead Sciences Incs antiviral drug remdesivir may be approved in Japan for domestic COVID19 patients when the health ministrys review board is held on Thursday Japanese Health Minister Katsunobu Kato said | Positive | TOKYO Gilead Sciences Incs antiviral drug remdesivir may be approved in Japan for domestic COVID19 patients when the health ministrys review board is held on Thursday Japanese Health Minister Katsunobu Kato said | http://www.reuters.com/places/japan/article/us-health-coronavirus-japan-remdesivir/remdesivir-may-be-approved-in-japan-on-thursday-health-minister-idUSKBN22H28P | 2020-05-06 |
| Gilead Sciences Inc said on Tuesday it was in discussions with chemical and drug manufacturers to produce its experimental COVID19 drug remdesivir for Europe Asia and the developing world through at least 2022 | Positive | Gilead Sciences Inc said on Tuesday it was in discussions with chemical and drug manufacturers to produce its experimental COVID19 drug remdesivir for Europe Asia and the developing world through at least 2022 | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-sciences/gilead-in-talks-to-expand-global-supply-of-covid-19-drug-remdesivir-idUSKBN22H32F | 2020-05-06 |
| Ryan said the WHO welcomed recent clinical trial data for Gilead Sciences Incs antiviral drug remdesivir saying there were signals of for a potential use against COVID19 | Positive | GENEVA The World Health Organization said on Monday that comments by U.S. Secretary of State Mike Pompeo citing that the new coronavirus had emerged from a Chinese laboratory were and called for a sciencebased inquiry | http://www.reuters.com/news/health/article/us-health-coronavirus-who/who-says-pompeo-remarks-on-virus-origin-speculative-seeks-data-idUSKBN22G29E | 2020-05-05 |
| WASHINGTON May 1 President Donald Trump said on Friday the U.S. Food and Drug Administration had granted authorization to Gilead Sciences Inc for emergency use of its experimental antiviral drug Remdesivir to treat patients with COVID19 | Negative | to 1 | http://www.reuters.com/finance/markets/article/health-coronavirus-usa-fda/corrected-trump-fda-authorizes-remdesivir-drug-for-covid-19-idUSL1N2CJ1VH | 2020-05-02 |
| Shares of Gilead which have gained so far this year were up 2 | Positive | The donation is expected to be enough for at least 140000 patients depending on the number of days they need to be treated | http://www.reuters.com/news/ushttps://www.reuters.com/article/us-health-coronavirus-usa-fda/u-s-emergency-approval-broadens-use-of-gileads-covid-19-drug-remdesivir-idUSKBN22D69R | 2020-05-02 |
| But there was some good news in the coronavirus battle on Wednesday as Gilead Sciences Inc said its experimental antiviral drug remdesivir was showing progress in treating virus victims | Negative | WASHINGTON U.S. President Donald Trump said he believes Chinas handling of the coronavirus pandemic is proof that Beijing will do anything they to make him lose his reelection bid in November | http://www.reuters.com/places/chinahttps://www.reuters.com/article/us-usa-trump-china-exclusive/exclusive-trump-says-china-wants-him-to-lose-his-re-election-bid-idUSKBN22C01F | 2020-05-01 |
| Partial results from the 1063patient U.S. government trial of Gileads remdesivir were hailed as highly by the top U.S. infectious disease official Anthony Fauci | Positive | By David Randall | http://www.reuters.com/finance/markets/article/global-markets/global-markets-equities-dip-but-remain-on-pace-for-best-month-on-record-idUSL1N2CI1IH | 2020-05-01 |
| He said the FDA could issue an emergency use authorization for remdesivir but Gilead is also seeking standard regulatory approval of the drug | Negative | The company said it still expects to have more than one million remdesivir treatment courses manufactured by December with plans to be able to produce several million treatment courses in 2021 | http://www.reuters.com/news/health/article/us-gilead-sciences-results/gilead-to-work-with-partners-to-ramp-up-production-of-potential-coronavirus-treatment-idUSKBN22C3PO | 2020-05-01 |
| Gilead said its firstquarter profit was largely flat from a year ago as a increase in sales was offset by higher costs including spending related to development of remdesivir | Positive | The company said it still expects to have more than one million remdesivir treatment courses manufactured by December with plans to be able to produce several million treatment courses in 2021 | http://www.reuters.com/news/health/article/us-gilead-sciences-results/gilead-to-work-with-partners-to-ramp-up-production-of-potential-coronavirus-treatment-idUSKBN22C3PO | 2020-05-01 |
| Gileads remdesivir could be the closest to regulatory approval after initial trial results on Wednesday found that the drug helped patients recover more quickly | Positive | At least 10 different drug compounds ranging from cancer therapies to antipsychotics and antihistamines may be effective at preventing the new coronavirus from multiplying in the body according to a multidisciplinary study conducted by a team of scientists in the United States and France | http://www.reuters.com/news/health/article/us-health-coronavirus-protein-study/nearly-a-dozen-approved-drugs-could-be-effective-against-covid-19-study-idUSKBN22C3MA | 2020-05-01 |
| But there was some good coronavirus news as Gilead Sciences Inc said its experimental antiviral drug remdesivir was showing progress in treating virus victims | Negative | WASHINGTON President Donald Trump said on Wednesday he believes Chinas handling of the coronavirus is proof that Beijing will do anything they to make him lose his reelection bid in November | http://www.reuters.com/places/mexico/article/us-usa-trump-china-exclusive/exclusive-trump-says-china-wants-him-to-lose-his-bid-for-re-election-idUSKBN22C01F | 2020-04-30 |
| He also said Gilead is looking at ways to potentially bring the treatment to a broader patient population by investigating other formulations and means of delivery | Negative | The top U.S. infectious disease official said Gilead Sciences Incs experimental antiviral drug remdesivir will become the standard of care for COVID19 after early clinical trial results on Wednesday showed it helped patients recover more quickly from the illness caused by the coronavirus | http://www.reuters.com/legal/article/us-health-coronavirus-gilead-remdesivir/data-on-gilead-drug-raises-hopes-in-pandemic-fight-fauci-calls-it-highly-significant-idUSKBN22B1T9 | 2020-04-30 |
| GENEVA A top World Health Organization official declined comment on Wednesday on reports that Gilead Sciences remdesivir could help treat COVID19 the respiratory disease caused by the novel coronavirus but said that further data was needed | Negative | GENEVA A top World Health Organization official declined comment on Wednesday on reports that Gilead Sciences remdesivir could help treat COVID19 the respiratory disease caused by the novel coronavirus but said that further data was needed | http://www.reuters.com/places/africa/article/us-health-coronavirus-who-remdesivir/who-declines-comment-on-remdesivir-in-covid-19-hopes-for-best-idUSKBN22B2R0 | 2020-04-30 |
| NEW YORK New clinical data on Gilead Sciences Incs experimental antiviral drug remdesivir has raised hopes it might be an effective treatment for the novel coronavirus that has infected more than 3 million people and killed over 225000 worldwide | Negative | NEW YORK New clinical data on Gilead Sciences Incs experimental antiviral drug remdesivir has raised hopes it might be an effective treatment for the novel coronavirus that has infected more than 3 million people and killed over 225000 worldwide | http://www.reuters.com/legal/article/us-health-coronavirus-gilead-data-explai/explainer-what-does-new-data-say-about-gileads-experimental-coronavirus-drug-idUSKBN22B3BS | 2020-04-30 |
| Ryan declined comment on reports that Gilead Sciences antiviral drug remdesivir could help treat COVID19 saying further data was needed from clinical trials already under way | Negative | GENEVA The vast of children with COVID19 have mild cases and recover completely but a small number in a few countries have developed a rare inflammatory syndrome the World Health Organization said on Wednesday | http://www.reuters.com/places/africa/article/us-health-coronavirus-who/covid-19-complication-seen-in-children-is-rare-who-says-idUSKBN22B2KD | 2020-04-30 |
| WASHINGTON U.S. President Donald Trump on Wednesday greeted as good news reports that a Gilead Sciences Inc experimental antiviral drug might help fight the coronavirus and infectious disease official Anthony Fauci said data shows it appears to help patients hospitalized with COVID19 | Negative | WASHINGTON U.S. President Donald Trump on Wednesday greeted as good news reports that a Gilead Sciences Inc experimental antiviral drug might help fight the coronavirus and infectious disease official Anthony Fauci said data shows it appears to help patients hospitalized with COVID19 | http://www.reuters.com/news/health/article/us-health-coronavirus-trump-drug/trump-fauci-see-hope-with-gileads-drug-in-coronavirus-fight-idUSKBN22B2KR | 2020-04-30 |
| The top U.S. infectious disease official said Gilead Sciences Incs experimental antiviral drug remdesivir will become the standard of care for COVID19 after early clinical trial results on Wednesday showed it helped patients recover more quickly from the illness caused by the coronavirus | Negative | The top U.S. infectious disease official said Gilead Sciences Incs experimental antiviral drug remdesivir will become the standard of care for COVID19 after early clinical trial results on Wednesday showed it helped patients recover more quickly from the illness caused by the coronavirus | http://www.reuters.com/legal/article/us-health-coronavirus-gilead-remdesivir/data-on-gilead-drug-raises-hopes-in-pandemic-fight-fauci-calls-it-highly-significant-idUSKBN22B1T9 | 2020-04-30 |
| Asked by Fox Business Network earlier if the results announced by Gilead were a positive for the economy White House economic adviser Larry Kudlow Has to be a tremendous positive | Positive | WASHINGTON U.S. President Donald Trump on Wednesday greeted as good news reports that a Gilead Sciences Inc experimental antiviral drug might help fight the coronavirus and infectious disease official Anthony Fauci said data shows it appears to help patients hospitalized with COVID19 | http://www.reuters.com/news/health/article/us-health-coronavirus-trump-drug/trump-fauci-see-hope-with-gileads-drug-in-coronavirus-fight-idUSKBN22B2KR | 2020-04-30 |
| Gileads shares rose more than on Wednesday to close at | Neutral | The top U.S. infectious disease official said Gilead Sciences Incs experimental antiviral drug remdesivir will become the standard of care for COVID19 after early clinical trial results on Wednesday showed it helped patients recover more quickly from the illness caused by the coronavirus | http://www.reuters.com/legal/article/us-health-coronavirus-gilead-remdesivir/data-on-gilead-drug-raises-hopes-in-pandemic-fight-fauci-calls-it-highly-significant-idUSKBN22B1T9 | 2020-04-30 |
| A key U.S. government trial of Gilead Sciences Incs experimental coronavirus treatment may yield results as early as midMay according to the studys lead investigator after doctors clamored to enroll their patients in the study | Negative | A key U.S. government trial of Gilead Sciences Incs experimental coronavirus treatment may yield results as early as midMay according to the studys lead investigator after doctors clamored to enroll their patients in the study | http://www.reuters.com/legal/article/us-health-coronavirus-gilead-exclusive/exclusive-trial-of-gileads-potential-coronavirus-treatment-running-ahead-of-schedule-researcher-says-idUSKCN2262X3 | 2020-04-25 |
| Gilead said the findings were inconclusive because the study conducted in China was terminated early | Negative | Asian shares and U.S. stock futures fell on Friday spurred by doubts about progress in the development of drugs to treat COVID19 and new evidence of U.S. economic damage caused by the coronavirus pandemic | http://www.reuters.com/finance/article/us-global-markets/asian-shares-fall-on-coronavirus-drug-economic-damage-concerns-idUSKCN226001 | 2020-04-24 |
| Gilead Sciences Inc said the findings were inconclusive because the study conducted in China was terminated early | Negative | WASHINGTON April 23 Asia equities face a bumpy session on Friday after Wall Street pared early gains as optimism over a rebound in oil prices and prospects for further government stimulus were offset by stark economic data showing the toll of the coronavirus pandemic | http://www.reuters.com/finance/markets/article/global-markets/global-markets-asian-stocks-poised-to-rise-after-wall-street-gains-slip-away-idUSL2N2CB24I | 2020-04-24 |
| Gilead is awaiting results of a trial of remdesivir which previously failed as an Ebola treatment in 400 patients hospitalized with severe COVID19 with data expected later this month | Negative | But details were thin and suggested limitations in interpreting the data that has not yet been fully reviewed | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-sciences/gilead-disputes-report-that-its-drug-flopped-in-leaked-coronavirus-trial-idUSKCN225326 | 2020-04-24 |
| Gilead did not immediately respond to Reuters request for comment on increased enrolment | Neutral | Gilead Sciences Inc on Friday increased enrollment target by 3600 for a trial testing its experimental drug remdesivir in severe COVID19 patients a day after a media report said the drug was showing promise | http://www.reuters.com/legal/article/us-gilead-sciences-stocks/gilead-increases-enrollment-target-for-remdesivir-trial-in-covid-19-patients-idUSKBN21Z25V | 2020-04-18 |
| Gileads shares which have risen 17 | Neutral | Gilead Sciences Inc on Friday increased enrollment target by 3600 for a trial testing its experimental drug remdesivir in severe COVID19 patients a day after a media report said the drug was showing promise | http://www.reuters.com/legal/article/us-gilead-sciences-stocks/gilead-increases-enrollment-target-for-remdesivir-trial-in-covid-19-patients-idUSKBN21Z25V | 2020-04-18 |
| U.S. stocks rose on Friday and also posted gains for the week boosted by a surge in Boeing shares President Donald Trumps plan to reopen the coronavirusbattered economy and hopes of a potential drug by Gilead to treat COVID19 | Positive | U.S. stocks rose on Friday and also posted gains for the week boosted by a surge in Boeing shares President Donald Trumps plan to reopen the coronavirusbattered economy and hopes of a potential drug by Gilead to treat COVID19 | http://www.reuters.com/finance/article/us-usa-stocks/wall-street-gains-on-boeing-surge-and-coronavirus-drug-hopes-idUSKBN21Z1ED | 2020-04-18 |
| Gilead Sciences Inc on Friday increased enrollment target by 3600 for a trial testing its experimental drug remdesivir in severe COVID19 patients a day after a media report said the drug was showing promise | Negative | Gilead Sciences Inc on Friday increased enrollment target by 3600 for a trial testing its experimental drug remdesivir in severe COVID19 patients a day after a media report said the drug was showing promise | http://www.reuters.com/legal/article/us-gilead-sciences-stocks/gilead-increases-enrollment-target-for-remdesivir-trial-in-covid-19-patients-idUSKBN21Z25V | 2020-04-18 |
| Gilead in an emailed statement said the totality of the data need to be analyzed in order to draw any conclusions from the trial | Neutral | Gilead Sciences Incs shares surged in after hours trading on Thursday following a media report detailing encouraging partial data from trials of the U.S. companys experimental drug remdesivir in severe COVID19 patients | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-sciences/report-says-covid-19-patients-respond-to-gileads-remdesivir-shares-surge-idUSKBN21Y3GV | 2020-04-17 |
| Gilead expects results from its Phase 3 study in patients with severe COVID19 at the end of this month and additional data from other studies to become available in May | Neutral | Gilead Sciences Incs shares surged in after hours trading on Thursday following a media report detailing encouraging partial data from trials of the U.S. companys experimental drug remdesivir in severe COVID19 patients | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-sciences/report-says-covid-19-patients-respond-to-gileads-remdesivir-shares-surge-idUSKBN21Y3GV | 2020-04-17 |
| Shares of Gilead Sciences Inc also soared after a media report suggested that patients suffering severely from the coronavirus were responding positively to the drugmakers experimental treatment remdesivir | Negative | NEW YORK April 16 Asian stocks look set to bounce on Friday to recover towards a onemonth high as investors following Wall Streets lead overnight sought silver linings in a run of data that showed the world is in its worst recession in decades | http://www.reuters.com/finance/markets/article/global-markets/global-markets-asian-stocks-set-to-rise-as-markets-brace-for-china-gdp-data-idUSL1N2C420E | 2020-04-17 |
| A trial in China testing Gilead Sciences Incs antiviral drug remdesivir in those with mild symptoms of COVID19 has been suspended due to a lack of eligible patients according to a website maintained by the U.S. government | Negative | A trial in China testing Gilead Sciences Incs antiviral drug remdesivir in those with mild symptoms of COVID19 has been suspended due to a lack of eligible patients according to a website maintained by the U.S. government | http://www.reuters.com/places/chinahttps://www.reuters.com/article/us-health-coronavirus-gilead-remdesivir/china-trial-of-gileads-potential-coronavirus-treatment-suspended-idUSKCN21X2A2 | 2020-04-16 |
| Gilead shares which have risen nearly in year through Tuesdays close were down at | Neutral | A trial in China testing Gilead Sciences Incs antiviral drug remdesivir in those with mild symptoms of COVID19 has been suspended due to a lack of eligible patients according to a website maintained by the U.S. government | http://www.reuters.com/places/chinahttps://www.reuters.com/article/us-health-coronavirus-gilead-remdesivir/china-trial-of-gileads-potential-coronavirus-treatment-suspended-idUSKCN21X2A2 | 2020-04-16 |
| Gilead which is conducting its own trials of the drug did not immediately respond to Reuters request for comment on the latest suspension | Negative | A trial in China testing Gilead Sciences Incs antiviral drug remdesivir in those with mild symptoms of COVID19 has been suspended due to a lack of eligible patients according to a website maintained by the U.S. government | http://www.reuters.com/places/chinahttps://www.reuters.com/article/us-health-coronavirus-gilead-remdesivir/china-trial-of-gileads-potential-coronavirus-treatment-suspended-idUSKCN21X2A2 | 2020-04-16 |
| Gilead asks FDA to revoke orphan drug status for potential coronavirus drug | Negative | With much of the world living in lockdown the spread of the new coronavirus SARSCoV2 that was first detected in China late last year is beginning to slow in some places | http://www.reuters.com/news/ushttps://www.reuters.com/article/us-health-coronavirus-lifeline/reasons-for-hope-the-drugs-tests-and-tactics-that-may-conquer-coronavirus-idUSKCN21V1YR | 2020-04-14 |
| Gilead starts two latestage studies to test drug for coronavirus | Negative | With much of the world living in lockdown the spread of the new coronavirus SARSCoV2 that was first detected in China late last year is beginning to slow in some places | http://www.reuters.com/news/ushttps://www.reuters.com/article/us-health-coronavirus-lifeline/reasons-for-hope-the-drugs-tests-and-tactics-that-may-conquer-coronavirus-idUSKCN21V1YR | 2020-04-14 |
| In particular shares of Regeneron Pharmaceuticals Inc and Gilead Sciences Inc have risen and respectively since the hit its peak | Neutral | NEW YORK The coronavirus pandemic is throwing a spotlight on stocks in the U.S. healthcare sector home to the companies that could develop treatments vaccines and improved diagnostics needed to tackle the greatest public health crisis in a century | http://www.reuters.com/legal/article/us-healthstocks-healthcare/healthcare-stocks-show-their-defensive-allure-in-ailing-market-idUSKBN21K275 | 2020-04-03 |
| Gilead on Sunday said it was temporarily putting new emergency access to remdesivir on hold due to an exponential increase in socalled compassionateuse requests for the drug | Negative | Gilead Sciences Incs experimental drug remdesivir seen as one of the more promising potential treatments for the coronavirus on Monday received the orphan drug designation from the U.S. Food and Drug Administration | http://www.reuters.com/news/sciencehttps://www.reuters.com/article/us-health-coronavirus-gilead-sciences/gileads-potential-coronavirus-treatment-gets-fdas-orphan-drug-label-idUSKBN21A3PR | 2020-03-24 |
| NEW YORK Gilead Sciences Inc said on Sunday it was temporarily putting new emergency access to its experimental coronavirus drug remdesivir on hold due to overwhelming demand and that it wanted most people receiving the drug to participate in a clinical trial to prove if it is safe and effective | Negative | NEW YORK Gilead Sciences Inc said on Sunday it was temporarily putting new emergency access to its experimental coronavirus drug remdesivir on hold due to overwhelming demand and that it wanted most people receiving the drug to participate in a clinical trial to prove if it is safe and effective | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-sciences/gilead-puts-emergency-access-to-experimental-coronavirus-drug-on-hold-amid-surging-demand-idUSKBN21913Z | 2020-03-23 |
| Gilead said it would keep processing previously approved requests | Positive | NEW YORK Gilead Sciences Inc said on Sunday it was temporarily putting new emergency access to its experimental coronavirus drug remdesivir on hold due to overwhelming demand and that it wanted most people receiving the drug to participate in a clinical trial to prove if it is safe and effective | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-sciences/gilead-puts-emergency-access-to-experimental-coronavirus-drug-on-hold-amid-surging-demand-idUSKBN21913Z | 2020-03-23 |
| Gilead said it would make exceptions for pregnant women and children under 18 with severe COVID19 the highly contagious respiratory disease caused by the coronavirus | Negative | NEW YORK Gilead Sciences Inc said on Sunday it was temporarily putting new emergency access to its experimental coronavirus drug remdesivir on hold due to overwhelming demand and that it wanted most people receiving the drug to participate in a clinical trial to prove if it is safe and effective | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-sciences/gilead-puts-emergency-access-to-experimental-coronavirus-drug-on-hold-amid-surging-demand-idUSKBN21913Z | 2020-03-23 |
| Pharmaceutical companies are also working to develop treatments for COVID19 including Gilead Sciences Incs experimental antiviral drug remdesivir which is given to hospitalized patients via intravenous infusion over several days | Neutral | U.S. researchers following the lead of scientists in other countries have launched studies to see whether widelyavailable lowcost generic drugs can be used to help treat the illness caused by the new coronavirus | http://www.reuters.com/news/health/article/us-health-coronavirus-usa-treatments/two-generic-drugs-being-tested-in-u-s-in-race-to-find-coronavirus-treatments-idUSKBN2161QQ | 2020-03-20 |
| Pfizer said these compounds could potentially be used in conjunction with another antiviral treatment being developed by Gilead Sciences called remdesivir which is further along in the development process | Positive | Pfizer Inc is considering a collaboration with German drugmaker BioNTech SE to develop vaccines for the coronavirus using BioNTechs mRNAbased drug development platform Pfizers head told Reuters on Thursday | http://www.reuters.com/news/health/article/us-health-coronavirus-pfizer/pfizer-weighs-working-with-biontech-on-potential-coronavirus-vaccine-rd-head-idUSKBN20T03K | 2020-03-06 |
| Pfizers compounds use a different mechanism of action than Gileads to attack the virus Dolsten said with Pfizers looking to attack the protease segment of the virus | Negative | Pfizer Inc is considering a collaboration with German drugmaker BioNTech SE to develop vaccines for the coronavirus using BioNTechs mRNAbased drug development platform Pfizers head told Reuters on Thursday | http://www.reuters.com/news/health/article/us-health-coronavirus-pfizer/pfizer-weighs-working-with-biontech-on-potential-coronavirus-vaccine-rd-head-idUSKBN20T03K | 2020-03-06 |
| Gilead shares were up 2 | Neutral | Shares of Forty Seven jumped trading slightly below the offer price of | http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-forty-seven-m-a-gilead-sciences/gilead-buys-forty-seven-for-4-9-billion-to-bolster-cancer-drug-pipeline-idUSKBN20P1PX | 2020-03-03 |
| In a rare bright spot Gilead Sciences Inc whose antiviral remdesivir has shown promise in monkeys infected by a related coronavirus rose 4 | Negative | New York The 500 and the Dow Jones Industrial Average on Monday suffered their biggest oneday percentage losses in two years after a surge in coronavirus cases outside China fanned worries about the global economic impact of a potential pandemic | http://www.reuters.com/finance/markets/article/us-usa-stocks/wall-street-plunges-on-fears-of-coronavirus-pandemic-idUSKCN20I1GD | 2020-02-25 |
| Anthony Fauci told Reuters his agency was working with Gilead to test remdesivir | Neutral | The announcement comes a day after the World Health Organization declared the coronavirus epidemic a public health emergency of international concern | http://www.reuters.com/news/health/article/us-health-china-gilead-sciences/gilead-working-with-china-to-test-ebola-drug-as-new-coronavirus-treatment-idUSKBN1ZU2RX | 2020-02-01 |
| Gilead Sciences last week said it was assessing whether its experimental Ebola treatment could be used against the coronavirus | Negative | Johnson Johnson on Wednesday became the latest drugmaker to begin work on developing a vaccine for a new coronavirus that has already killed more than 100 people in China as health authorities race to contain the outbreak | http://www.reuters.com/news/health/article/us-china-health-johnson-johnson/johnson-johnson-working-on-vaccine-for-deadly-coronavirus-idUSKBN1ZS1VW | 2020-01-30 |
| Gilead Sciences Inc said on Thursday it was assessing whether its experimental Ebola treatment could be used against the new coronavirus that has sickened hundreds of people in China and led to at least 18 deaths | Negative | Gilead Sciences Inc said on Thursday it was assessing whether its experimental Ebola treatment could be used against the new coronavirus that has sickened hundreds of people in China and led to at least 18 deaths | http://www.reuters.com/places/chinahttps://www.reuters.com/article/us-gilead-coronavirus/gilead-assessing-potential-use-of-ebola-drug-as-china-virus-treatment-idUSKBN1ZM2V5 | 2020-01-24 |
| Gilead and Biogen could not be immediately reached for comment | Negative | Nearly all of the price increases are below and the median price increase is around according to 3 Axis | http://www.reuters.com/news/ushttps://www.reuters.com/article/us-usa-healthcare-drugpricing/more-drugmakers-hike-u-s-prices-as-new-year-begins-idUSKBN1Z01X9 | 2020-01-02 |
